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JOURNAL OF HEPATOLOGYReply to: ‘‘Direct actions of GLP-1 analogues on AMP-activated
protein kinase activity are distinct from cyclic AMP accumulation’’To the Editor:
We thank Dr Samson for her valuable comments.
First of all, wewould like to emphasize that, in our study [1], we
have mechanistically focused on the association between GLP-1
and phosphorylated AMP-activated kinase (pAMPK). Indeed, by
using a dominant negative AMPK mutant adenovirus, we have
proved that AMPK directly mediates GLP-1 action on lipogenesis
in hepatocytes [1]. We have by no means intended to decipher
the connection between the cAMPandAMPKpathways, and in this
respect, we have relied upon recent published peer review litera-
ture. We do agree with the authors’ claim that we should not have
used phrases such as ‘‘cAMP/AMPK’’ pathways, without discussing
this possible pathway in the Discussion section of our article.
In most cells, intracellular cAMP signaling is mediated by two
groups of effectors that bind to cAMP: protein kinase A and
exchange proteins directly activated by cAMP (Epac) [2]. Accu-
mulating data point to a pathway linking cAMP and AMPK activa-
tion via Epac and, therefore, we disagree with the authors’
statement that ‘‘There is no evidence that cAMP has any direct role
in the regulation of AMPK activity’’.
The ﬁrst evidence linking cAMP and AMPK has emerged from
studies in adipocytes [3,4]. Yin et al. have demonstrated in 3T3-
L1 adipocytes that cAMP induction by forskolin promotes AMPK
phosphorylation through activation of Thr-172 residues in a dose
and time dependent manner [3]. Later, Fu et al. have described in
hepatocytes a unique pathway in which taurocholate promotes
bile canaliculi network formation [5]. In this study, combining
molecular and pharmacologic approaches, the authors have
delineated the pathway in a step-wise manner and have found
that taurocholate increases cAMP, leading to activation of Epac
and its downstream molecules Rap1 and MEK. This signaling
pathway has been directly related to liver kinase B1 (LKB1) and
AMPK activation. Importantly, pharmacologic PKA inhibition
does not block the described cascade [5].
Another recent study investigating the anti-diabetogenic
properties of resveratrol has found that this molecule acts as a
phosphodiesterase inhibitor, enhancing cAMP levels and activat-
ing AMPK in an Epac1 dependent manner [6]. Again, this pathway
is not dependent on PKA activation.
Taken together, the cited literature does show that cAMP can
lead to activation of AMPK.
The authors claim that cAMP and AMPK have different roles in
hepatocytes; however, both molecules indicate a low energy
state in the cell. Indeed, while our article describes an anti-lipo-Journal of Hepatology 20genic role for GLP-1, a known effect of both signals, we have
found no effect of GLP-1 with regard to gluconeogenesis, a pro-
cess regulated in an opposite manner by the two signals.
With regard to the presence of pancreatic GLP-1R on hepato-
cytes, it is indeed a controversial issue. However, several groups
have demonstrated the presence of this receptor on hepatocytes,
including human hepatocytes, and have also shown that GLP-1
increases cAMP in hepatocytes [7–9]. One of the articles showing
expression of GLP-1R on hepatocytes is cited by the authors
themselves [9].
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Are Hedgehog and Wnt/b-catenin pathways involved in
hepatitis C virus-mediated EMT?
To the Editor:
We read with great interest the article by Akkari et al. [1], who
evaluated the EMT induction and correlated oncogenic transfor-
mation induced by HCV protein NS5A in primary hepatocyte
precursors.
Epithelial–mesenchymal transition (EMT) is a biological pro-
cess occurring during tissue development and regeneration,
moreover, it is known to be involved in tumor progression and
metastasis. The EMT is a phenomenon, which well represents
the cellular plasticity, i.e., the ability of polarized epithelial cells,
which through multiple biochemical changes acquire a mesen-
chymal cell phenotype. These cells exhibit loss of cell adhesion,
enhanced migratory capacity, invasiveness, elevated resistance
to apoptosis and a great ability to produce extracellular matrix
(ECM) components. Several molecular processes are involved in
EMT onset and progression. Among them we have to mention:
activation of transcription factors (e.g., Snail, Twist, etc.), expres-
sion of speciﬁc cell-surface proteins, remodelling of cytoskeletal
components, production of ECM-degrading enzymes and changes
in the expression of speciﬁc microRNAs (e.g., microRNA 200 fam-
ily). Most of them are commonly used as biomarkers to highlight
a cellular EMT [2,3].
Akkari et al. have evaluated how a viral protein can alter the
typical epithelial architecture of hepatic cells. In particular, they
demonstrated that the ectopic expression of hepatitis C virus
(HCV) non-structural protein 5a (NS5A) is able to induce EMT
in bipotential mouse embryonic liver (BMEL) cells which acquire
mesenchymal phenotype, increased motility and invasiveness,
and are featured by the downregulation of epithelial markers
(e.g., E-Cadherin) and the upregulation of mesenchymal markers
(like Vimentin and Twist2). They also conﬁrmed their results in
an in vivo xenograft mouse model.
To unravel the molecular mechanisms involved in EMT occur-
rence, they focused their experimental investigation on trans-
forming growth factor (TGF)-b, a main cytokine involved in
EMT induction. They have shown that NS5A is not responsible
for TGF-b pathway activation but it acts in a synergistic manner
with the cytokine in inducing EMT. Furthermore, they also
screened, in their in vitro model, the modulation of expression
of EMT biomarkers, such as Snail, Slug, Zeb and Twist 1/2. They
demonstrated that only Twist2 expression was speciﬁcally
increased by NS5A protein, and that, accordingly, through short
hairpin RNA against Twist2, they were able to counteract EMT
occurrence. Interestingly, the TGF-b treatment of cells lacking of
Twist2 is able to promote EMT in any case, suggesting that
NS5A and TGF-b trigger EMT by distinct pathways and thus
identifying Twist2 as an NS5A EMT speciﬁc effector.
Unfortunately, as the authors stated in the discussion ses-
sion, currently the mechanisms underlying Twist2 involvement
in NS5A-dependent and TGF-b-independent EMT are not yet
known.
Regarding the HCV context, it is well known that NS5A activ-
ities are strictly connected to many cellular proteins and have an
impact on several signaling pathways like, for instance, the
hedgehog (HH) pathway [4]. This correlation is really interesting,
because the HH pathway has emerged as an important mediator
of liver cancer pathogenesis [5]. Recently, this pathway was
involved in the reprogramming of cancer cells via EMT. In fact,
the upregulation of HH was associated with increased cell motil-
ity, invasion and tumor cell aggressiveness [5].
It is interesting to underline that different liver cell lines, such
as HuH 7.5 and LH86, which are featured by high expression lev-
els of HH pathway genes (e.g., sonic hedgehog (SHH), glioblas-
toma protein 1 (Gli1), and patched (PTC)), are the most diffuse
cells supporting a high HCV replication rate. It was also demon-
strated that the upregulation of mesenchymal markers and the
downregulation of epithelial markers were deeply connected to
HH signaling [4].
Besides the intracellular pathways governed by HH, Wnt/b-
catenin pathway is known to have a role in EMT induction [3].
This pathway could be strikingly relevant, because it is also
involved in HCV-related neoplastic transformation and EMT
onset [6,7].
The authors suggest that the mechanism underlying EMT
caused by HCV is reallymore intricate andmay involve a lot of sig-
naling pathways, like HH and Wnt/b-catenin, which are already
known to be involved in organogenesis and cell transformation.
Our preliminary data obtained through the use of an in vitro
model of HCV infection, such as HuH 7.5 cells infected with the
full length chimeric HCV strain J6/JFH1, at 48 h after infection
indicate a signiﬁcant upregulation of the EMT marker gene,
Twist1 (fold change: 16.55 ± 0.20) and several molecules involved
in Wnt/b-catenin pathway such as: Wnt5a (fold change:
5.32 ± 0.32), Wnt5b (fold change: 3.60 ± 0.11), and LRP5 (fold
change: 5.12 ± 0.15). Taken into account the high expression lev-
els of HH pathway components in our cell model, our results sug-
gest that during HCV infection with a complete viral strain, other
genes involved in the EMT induction, i.e., Twist1, may be
upregulated.
In conclusion, a deep investigation of the intricate molecular
pathways modulated by HCV should be considered in order to
improve the existent know-how and to identify new potential
therapeutic targets useful to develop innovative and effective tar-
geted therapies against the HCV-related liver diseases.
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